{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"REVERCE II","nct_id":"NCT04117945","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=reverce-ii-nct04117945. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive regorafenib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.","label":"Arm A (regorafenib)","type":"EXPERIMENTAL"},{"description":"Patients receive cetuximab or panitumumab IV over 30-90 minutes on days 1 and 15. Patients may also receive irinotecan IV on days 1 and 15 as determined by the study doctor. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. If received as initial treatment, patients who experience disease progression may switch over to the other treatment regimen, per treating physician discretion.","label":"Arm B (cetuximab, panitumumab, irinotecan)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2025-03-31","type":"ESTIMATED"},"conditions":["BRAF V600E Negative","KRAS Gene Mutation Negative","Locally Advanced Unresectable Colorectal Adenocarcinoma","Metastatic Colorectal Adenocarcinoma","NRAS Gene Mutation Negative","Stage III Colorectal Cancer AJCC v8","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8"],"enrollment":{"count":22,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cetuximab","otherNames":["Cetuximab Biosimilar CDP-1","Cetuximab Biosimilar CMAB009","Cetuximab Biosimilar KL 140","Chimeric Anti-EGFR Monoclonal Antibody","Chimeric MoAb C225","Chimeric Monoclonal Antibody C225","Erbitux","IMC-C225"],"type":"BIOLOGICAL"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"},{"name":"Panitumumab","otherNames":["ABX-EGF","ABX-EGF Monoclonal Antibody","ABX-EGF, Clone E7.6.3","MoAb ABX-EGF","Monoclonal Antibody ABX-EGF","Vectibix"],"type":"BIOLOGICAL"},{"name":"Regorafenib","otherNames":["BAY 73-4506","Stivarga"],"type":"DRUG"}],"last_update":"2024-09-27","lead_sponsor":"Academic and Community Cancer Research United","official_title":"A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2023-09-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"20 months"}],"references":[],"start_date":{"date":"2020-03-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT04117945"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/reverce-ii-nct04117945"}